BioLife Solutions Inc (BLFS)vsMerck & Company Inc (MRK)
BLFS
BioLife Solutions Inc
$38.61
0.00%
HEALTHCARE · Cap: $1.89B
MRK
Merck & Company Inc
$143.65
-1.59%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 62296% more annual revenue ($66.57B vs $106.69M). BLFS leads profitability with a 54.3% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.71. BLFS earns a higher WallStSmart Score of 46/100 (D+).
BLFS
Hold46
out of 100
Grade: D+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.6%
Fair Value
$21.68
Current Price
$38.61
$16.93 premium
Margin of Safety
-72.1%
Fair Value
$83.44
Current Price
$143.65
$60.21 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 54.3% and operating margin at 6.0%. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BLFS
The primary concerns for BLFS are P/E Ratio, Market Cap, PEG Ratio.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BLFS profiles as a growth stock while MRK is a value play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.82 — expect wider price swings.
BLFS is growing revenue faster at 21.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BLFS scores higher overall (46/100 vs 36/100), backed by strong 54.3% margins and 21.5% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?